Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.

Abstract

Imatinib mesylate (IM, Glivec) and the 2 generation tyrosine kinase inhibitors (TKIs) (dasatinib and nilotinib) are the standard treatment for children and adults with chronic myeloid leukemia (CML). IM inhibits all ABL tyrosine kinases and selectively suppresses the ATP-binding site of platelet-derived growth factor receptor (PDGF-R) and c-KIT that are… (More)
DOI: 10.3324/haematol.2012.067447

Topics

2 Figures and Tables

Cite this paper

@article{Giona2013BoneMG, title={Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.}, author={Fiorina Giona and Stefania Mariani and Lucio Gnessi and Maria Luisa Moleti and Massimiliano Rea and Annalisa De Vellis and Deborah Marzella and Anna Maria Testi and Robin Fo{\'a}}, journal={Haematologica}, year={2013}, volume={98 3}, pages={e25-7} }